Opinion statement
The natural history of non-muscle invasive bladder cancer is characterized by a high probability of recurrence and in the case of high-grade tumors, progression to muscle invasive cancer. This mandates a follow-up strategy designed to identify recurrences in the bladder early in their evolution in order to facilitate early intervention and ablation. Urine cytol-ogy is considered the gold standard urine biomarker. Although specificity exceeds 90% to 95%, its overall sensitivity ranges from 40% to 60% in expert hands and is both tumor grade and operator dependent. While cytology is an excellent test for detection of high-grade disease, the sensitivity is particularly weak for the detection of low grade tumors. This has spawned an entire field of research of in vitro diagnostic tests and cell-based assays in order to improve the diagnostic accuracy for detection of incident or recurrent disease. To date, the US Food and Drug Administration approved dipstick and immunoassays marketed as point-of-care tests. The point-of-care tests are intended for use as an adjunct to cystoscopy and cytology, and may have a role in the office evaluation of hema-turia patients. Monoclonal antibody-based tests combined with cytology may improve the diagnostic accuracy and are superior to cytology alone. A recently approved cell-based assay, utilizing fluorescent in situ hybridization technology, may help resolve suspicious cytologies, and provide early and additional information about the biology of the bladder urothelium beyond that provided by cytology, a marker of disease relatively late in evolution. Novel promising markers are in various stages of clinical testing, and a panel of biomarkers may serve in the future as a feasible alternative to urine cytology and cystos-copy for the screening, detection, and follow-up of non-muscle invasive bladder cancer.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References and Recommended Reading
Blumenstein BA, Ellis WJ, Ishak LM: The relationship between serial measurements of the level of a bladder tumor associated antigen and the potential for recur-rence. J Urol 1999, 161:57–60. Presents a new method to evaluate the diagnostic perfor-mance of a marker for bladder cancer. Analysis of their cases showed that log of a quantitative diagnostic marker (QDM) and a history of tumor recurrence within 9 months before entry into the trial correlated with tumor recurrence, while neither grade nor remote history of recurrent TCC did. For every 10-fold increment in the QDM level there is a 60% increase in the hazard for bladder tumor recurrence. There-fore, evaluating these data in this manner rather than with conventional sensitivity and specificity calculations may present a more reliable estimate of the utility of voided urine diagnostic tests.
Sarosdy MF, deVere White RW, Soloway MS, et al.: Results of a multicenter trial using the BTA test to monitor for and diagnose recurrent bladder cancer [see comments]. J Urol 1995, 154:379–384.
Leyh H, Mazeman E: Bard BTA test compared with voided urine cytology in the diagnosis of recurrent bladder cancer. Eur Urol 1997, 32:425–428.
Droller MJ: Current concepts of tumor markers in bladder cancer. Urol Clin North Am 2002, 29:229–234.
Halachmi S, Linn JF, Amiel GE, et al.: Urine cytology, tumour markers and bladder cancer. Br J Urol 1998, 82:647–654.
Pirtskkalaishvilli G, Getzenberg RH, Konety BR: Use of urine-based markers for detection and monitoring of bladder cancer. Tech Urol 1999, 5:179–184.
Johnston B, Morales A, Emerson L, Lundie M: Rapid detection of bladder cancer: a comparative study of point-of-care tests. J Urol 1997, 158:2098–2101.
Leyh H, Marberger M, Conort P, et al.: Comparison of the BTA stat test with voided urine cytology and blad-der wash cytology in the diagnosis and monitoring of bladder cancer. Eur Urol 1999, 35:52–56.
Kinders R, Root R, Jones T, et al.: Complement factor H-related proteins are expressed in bladder cancers. Can-cer Res 1997, 38:29A.
Sarosdy MF, Hudson MA, Ellis WJ, et al.: Improved detection of recurrent bladder cancer using the BARD BTA stat Test. Urol 1997, 50:349–353.
Raitanen MP, Marttila T, Kaasinen E, et al.: Sensitivity of human complement factor H related protein (BTA stat) test and voided urine cytology in the diagnosis of bladder cancer. J Urol 2000, 163:1689–1692.
Ellis WJ, Blumenstein BA, Ishak LM, et al.: Clinical eval-uation of the BTA TRAK assay and comparison to voided urine cytology and the Bard BTA test in patients with recurrent bladder tumors. Urology 1997, 50(6):882–887.
Ishak LM, Ellis WJ: A comparison of the BTA stat and the BTA trak assays: 2 new tests for the detection of current bladder cancer in urine [abstract]. J Urol 1998, 59(5):936.
Carpinito GA, Stadler WM, Briggman JV, et al.: Urinary nuclear matrix protein as a marker for transitional cell carcinoma of the urinary tract. J Urol 1996, 156(4):1280–1285.
Keesee SK, Briggman JV, Thill G, Wu YJ: Utilization of nuclear matrix proteins for cancer diagnosis. Crit Rev Eukaryot Gene Expr 1996, 6:189–214.
Soloway MS, Briggman V, Carpinito GA, et al.: Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carci-noma of the urinary tract following surgical treat-ment. J Urol 1996, 156(2):363–367.
Zippe C, Pandrangi L, Agarwal A: NMP22 is a sensitive, cost-effective test in patients at risk for bladder can-cer. J Urol 1999, 161:62–65.
Stampfer DS, Carpinito GA, Rodriguez-Villanueva J, et al.: Evaluation of NMP22 in the detection of transi-tional cell carcinoma of the bladder. J Urol 1998, 159:394–398.
Shariat SF, Casella R, Wians FH Jr, et al.: Risk stratifica-tion for bladder tumor recurrence, stage, and grade by urinary nuclear matrix protein 22 and cytology. Eur Urol 2004, 45:304–13. The authors of this paper introduced the concept of a panel of urine tumor markers: diagnostic sensitivities of the combined NMP22 and cytology for TCC presence, stage, and grade were significantly higher than those of a single marker alone. They concluded that combination of urine cytology and NMP22 could be used to tailor the frequency of cystoscopic follow-up.
Ohori M, Kattan MW, Koh H, et al.: Predicting the pres-ence and side of extracapsular extension: a nomogram for staging prostate cancer. J Urol 2004, 171(5):1844- 1849; discussion 1849.
Sharma S, Zippe CD, Pandrangi L, et al.: Exclusion crite-ria enhance the specificity and positive predictive value of NMP22 and BTA stat. J Urol 1999, 162:53–57.
US Food and Drug Administration: Guidance docu-ment for the submission of tumor associated antigen premarket notifications. http://www.fda.gov/cdrh/ode/ tumor821.html
Sagerman PM, Saigo PE, Scheinfield J, et al.: Enhanced detection of bladder cancer in urine cytology with Lewis X, M344 and 19A211 antigens. Acta Cytol 1994, 38:517–523.
Lee E, Schwaibold H, Fradet Y, et al.: Tumour-associated antigens in normal mucosa of patients with superfi-cial transitional cell carcinoma of the bladder. J Urol 1997, 157:1070–1073.
Mian C, Pycha A, Wiener H, et al.: ImmunoCyt: a new tool for detecting transitional cell cancer of the uri-nary tract. J Urol 1999, 161:1486–1489.
Halling KC, King W, Sokolova IA, et al.: A comparison of cytology and fluorescence in situ hybridization for the detection of urothelium carcinoma. J Urol 2000, 164:1768–1776.
Skacel M, Fahmy M, Brainard JA, et al.: Multitarget fluo-rescence in situ hybridization assay detects transi-tional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytol-ogy. J Urol 2003, 169:2101–2105. The authors evaluated the ability of FISH to identify malig-nant cells in cytologically equivocal or negative cases. This is a unique and challenging group of patients for clinicians. In addition to providing high sensitivity and specificity, this test was able to detect eight of nine patients (89%) with initial atypical cytology and a negative concurrent bladder biopsy, that produced a biopsy-proven TCC within 12 months follow-ing the date when the sample tested by FISH was obtained.
Ishiwata S, Takahashi S, Homma Y, et al.: Noninvasive detection and prediction of bladder cancer by fluores-cence in situ hybridization analysis of exfoliated urothelial cells in voided urine. Urology 2001, 57(4):811–815.
Getzenberg RH, Konety BR, Oeler TA, et al.: Bladder cancer associated nuclear matrix proteins. Cancer Res 1996, 56:1690–1694.
Konety BR, Nguyen T-S, Brenes G, et al.: Clinical useful-ness of the novel marker, BLCA-4, for the detection of bladder cancer. J Urol 2000, 164:634–639.
Van Le TS, Myers J, Konety BR, et al.: Functional charac-terization of the bladder cancer marker, BLCA-4. Clini-cal Cancer Res 2004, 10:1384–1391.
Mavrothalassitis G, Ghysdael J: Proteins of the ETS family with transcriptional repressor activity. Onco-gene 2000, 19:6524–6532.
Van Le T-S.T, Miller R, Barder, et al.: A highly specific urine-based marker of bladder cancer. Cancer Research, submitted, 2004.
Rhyu MS: Telomeres, telomerase and immortality. J Natl Cancer Inst 1995, 87:884–894.
Yoshida K, Sugino T, Tahara H, et al.: Telomerase activ-ity in bladder carcinoma and its implication for non-invasive diagnosis by detection of exfoliated cancer cells in urine. Cancer 1997, 79:362–369.
Rahat MA, Lahat N, Gazawi H, et al.: Telomerase activ-ity in patients with transitional cell carcinoma. Cancer 1999, 85:919–924.
Kavaler E, Landman J, Chang Y, et al.: Detecting human bladder cancer cells in voided urine samples by assay-ing for the presence of telomerase activity. Cancer 1998, 82:708–714.
Lokeshwar V, Soloway M: Current bladder tumor tests: Does their projected utility fulfill clinical necessity? J Urol 2001, 165:1067–77.
Muller M, Krause H, Heicappell R, et al.: Comparison of human telomerase RNA and telomerase activity in urine for diagnosis of bladder cancer. Clin Cancer Res 1998, 4:1949–1954.
de Kok JB, Ruers TJ, van Muijen GN, et al.: Real-time quantification of human telomerase reverse tran-scriptase mRNA in tumours and healthy tissues. Clin Chem 2000, 46:313–318.
Ito H, Kyo S, Kanaya T, et al.: Detection of human telomerase reverse transcriptase messenger RNA in voided urine samples as a useful diagnostic tool for bladder cancer. Clin Cancer Res 1998, 4:2807–2810.
Velculescu VE, Madden SL, Zhang L, et al.: Analysis of human transcriptomes. Nat Genet 1999, 23:387–388.
Altieri DC: The molecular basis and potential role of surviving in cancer diagnosis and therapy. Trends Mol Med 2001, 7:542.
Swana HS, Grossman D, Anthone JN, et al.: Tumor con-tent of antiapoptosis molecule survivin and recurrence of bladder cancer. N Engl J Med 1999, 341:452–453.
Smith SD, Wheeler MA, Plescia J, et al.: Urine detection of survivin and diagnosis of bladder cancer. JAMA 2001, 285:324–328.
Shariat SF, Casella R, Khoddami SM, et al.: Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer. J Urol 2004, 171:626–630.
Matsumara Y, Sugiyama M, Matsumara S, et al.: Unusual retention of introns in CD44 gene transcripts in blad-der cancer provides new diagnostic and clinical onco-logical opportunities. J Pathol 1995, 177:11–20.
Woodman AC, Sugiyama M, Yoshida K, et al.: Analysis of anomalous CD44 gene expression in human breast, bladder, and colon cancer and correlation of observed mRNA and protein isoforms. Am J Pathol 1996, 149:1519–1530.
Matsumara Y, Hanbury D, Smith J, Tarin D: Non-inva-sive detection of malignancy by identification of unusual CD44 gene activity in exfoliated cancer cells. BMJ 1994, 308:619–624.
Sugiyama M, Woodman A, Sugino T, et al.: Noninvasive detection of bladder cancer by identification of abnormal CD44 proteins in exfoliated cancer cells in urine. J Clin Pathol Mol Pathol 1995, 48:142–147.
Lokeshwar VB, Block NL: HA-HAase urine test. A sensi-tive and specific method for detecting bladder cancer and evaluating its grade. Urol Clin North Am 2000, 27:53–61.
Lokeshwar VB, Obek C, Pham HT, et al.: Urinary hyalu-ronic acid and hyaluronidase: markers for bladder cancer detection and evaluation of grade. J Urol 2000, 163:348–356.
Heicappell R, Schostack M, Muller M, Miller K: Evalua-tion of urinary bladder cancer antigen as a marker for diagnosis of transitional cell carcinoma of the urinary bladder. Scand J Clin Lab Invest 2000, 60:275–282.
Sanchez-Carbayo M, Herrero E, Megias J, et al.: Initial evaluation of the diagnostic performance of the new urinary bladder cancer antigen test as a tumor marker for transitional cell carcinoma of the bladder. J Urol 1999, 161:1110 - 1115.
Sumi S, Arai K, Kitahara S, Yoshida KI: Preliminary report of the clinical performance of a new urinary bladder cancer antigen test: comparison to voided urine cytology in the detection of transitional cell carcinoma of the bladder. Clin Chim Acta 2000, 296:111–120.
Mian C, Lodde M, Haitel A, et al.: Comparison of two qualitative assays, the ubc rapid test and the bta stat test, in the diagnosis of urothelial cell carcinoma of the bladder. Urology 2000, 56:228–231.
Konety BR, Getzenberg R: Urine based markers of uro-logical malignancy. J Urol 2001, 165:600–611.
Sheinfeld J, Reuter VE, Melamed MR, et al.: Enhanced bladder cancer detection with the Lewis X antigen as a marker of neoplastic transformation. J Urol 1990, 143:285–288.
Pode D, Golijanin A, Sherman Y, et al.: Immunostain-ing of Lewis X in cells from voided urine, cytopathol-ogy and ultrasound for non-invasive detection of bladder tumours. J Urol 1998, 159:389–393.
Toma MI, Friedrich MG, Hautamann SH, et al.: Compar-ison of the ImmunoCyt test and urinary cytology with other urine tests in the detection and surveillance of bladder cancer. World J Urol 2004, In press [Epub ahead of print].
Mao L, Schoenberg MP, Scicchitano M, et al.: Molecular detection of primary bladder cancer by microsatellite analysis. Science 1996, 271:659–662.
Steiner G, Schoenberg MP, Linn JF, et al.: Detection of bladder cancer recurrence by microsatellite analysis of urine. Nat Med 1997, 3:621–624.
Mourah S, Cussenot O, Vimont V, et al.: Assessment of microsatellite instability in urine in the detection of transitional cell carcinoma of the bladder. Int J Cancer 1998, 79:629–633.
Linn JF, Lango M, Halachmi S, et al.: Microsatellite anal-ysis and telomerase activity in archived tissue and urine samples of bladder cancer patients. Int J Cancer 1997, 74:625–629.
Sardi I, Bartoletti R, Occhini I, et al.: Microsatellite alterations in superficial and locally advanced transi-tional cell carcinoma of the bladder. Oncol Rep 1999, 6:901–905.
Grossman HB, Liebert M, Flint A, Washington RW: Iden-tification by monoclonal of an antigen shed by human bladder cancer cells. Cancer Res 1989, 49(23):6720–6726.
Bonner RB, Liebert M, Hurst RE, et al.: Characterization of the DD23 tumor-associated antigen for bladder cancer detection and recurrence monitoring. Cancer Epidemiol Biomarkers Prev 1996, 5(12):971–978.
Hudson MA, McReynold LM: Urokinase (u-PA) and the u-PA receptor. Modulation of in vitro invasiveness of human bladder cancer cell lines. Adv Exp Med Biol 1999, 462:399–412.
Duffy MJ, Maguire TM, McDermott EW, O’Higgins N: Urokinase study is the first study to examine the util-ity of urinary levels of uPA and uPAR for the detection of bladder plasminogen activator: a prognostic marker in multiple types of cancer. J Surg Oncol 1999, 71:130–135.
Blasi F: The urokinase receptor. A cell surface, regu-lated chemokine. APMIS 1999, 107:96–101.
Casella R, Shariat SF, Monoski MA, Lerner SP: Urinary levels of urokinase-type plasminogen activator and its receptor in the detection of bladder carcinoma. Cancer 2002, 95:2494–2499.
Shariat SF, Casella R, Monoski MA, et al.: The addition of urinary urokinase-type plasminogen activator to urinary nuclear matrix protein 22 and cytology improves the detection of bladder cancer. J Urol 2003, 170:2244–2247.
Soloway MS, Bruck DS, Kim SS: Expectant management of small, recurrent, noninvasive papillary bladder tumors. J Urol 2003, 170:438–441.
Lotan Y, Roehrborn CG: Cost-effectiveness of a modi-fied care protocol substituting bladder tumor markers for cystoscopy for the follow-up of patients with tran-sitional cell carcinoma of the bladder: a decision ana-lytical approach. J Urol 2002, 167:75–79. The authors demonstrated for the first time, that using a mod-ified follow-up protocol in TCC cases with an initial tumor occurrence using a urine based tumor marker alternating with cystoscopy and/or cytology is costeffective for a wide range of marker sensitivities, specificities and costs.
Zippe C, Pandrangi L, Potts JM, et al.: Nmp22: a sensi-tive, cost-effective test in patients at risk for bladder cancer. Anticancer Res 1999, 19:2621–2623.
Simon MA, Lokeshwar VB, Soloway MS: Current blad-der cancer tests: unnecessary or beneficial? Crit Rev Oncol Hematol 2003, 47:91–107.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Amiel, G.E., Shu, T. & Lerner, S.P. Alternatives to cytology in the management of non-muscle invasive bladder cancer. Curr. Treat. Options in Oncol. 5, 377–389 (2004). https://doi.org/10.1007/s11864-004-0028-0
Issue Date:
DOI: https://doi.org/10.1007/s11864-004-0028-0